Program
mRNA COVID-19 Vaccine
Also written as “COVID-19 mRNA vaccine”, “COVID-19 mRNA Vaccine (ZSVG-02-O)” and “COVID-19 mRNA Vaccine (nucleoside modified)”.
Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections · Influenza, Human · Severe Acute Respiratory Syndrome, led by 10 companies.
Drug pageMRNA COVID-19 Vaccine: every studyMany companies study it; this page follows only the 13 they lead. All 18 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CanSino Biologicsits history only | 20 open or running | phase 2since May 12, 2022 | May 12, 2022 | none ahead |
| CNBG-Virogin Biotech (Shanghai)its history only | 22 open or running | phase 2since Oct 31, 2023 | Oct 31, 2023 | none ahead |
| Sanofiits history only | 20 open or running | phase 2since Mar 11, 2021 | Mar 11, 2021 | none ahead |
| Argorna Pharmaceuticalsits history only | 10 open or running | phase 1since May 28, 2023 | May 28, 2023 | none ahead |
| Bayer | 10 open or running | phase 3since Apr 16, 2021 | Apr 16, 2021 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 3since Apr 16, 2024 | Apr 16, 2024 | none ahead |
| Invivydits history only | 10 open or running | phase 3since Jun 8, 2026 | Jun 8, 2026 | none ahead |
| Stemirna Therapeuticsits history only | 10 open or running | phase 2since Nov 11, 2021 | Nov 11, 2021 | none ahead |
| Vaccineits history only | 10 open or running | phase 1since Jul 5, 2023 | Jul 5, 2023 | none ahead |
| Walvax Biotechnologyits history only | 10 open or running | phase 3since Apr 13, 2021 | Apr 13, 2021 | none ahead |
Also a collaborator on its studies: Abogen Biosciences and BioNTech.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Bayer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2021First study: phase 3 study in COVID-19First studyNCT04848467
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“mRNA COVID-19 Vaccine”name, by rule
Studies
The one study Bayer leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04848467COVID-19 | 3 | Withdrawn | Nov 30, 2021 | 0 |
How it is read
Names in the registry
- “COVID-19 mRNA vaccine”, 6 entries
- “COVID-19 mRNA Vaccine (ZSVG-02-O)”, 2 entries
- “COVID-19 mRNA Vaccine (nucleoside modified)”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 1”, 1 entry
- “SARS-CoV-2 mRNA vaccine formulation 2”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 9 studies
- Respiratory Syncytial Virus Infections, 1 study
- Influenza, Human, 1 study
- Severe Acute Respiratory Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.